Loading clinical trials...
Loading clinical trials...
PROTOCOL FOR PHASE II CLINICAL TRIAL, RANDOMIZED AND OPEN FOR ETIOLOGICAL TREATMENT OF CHRONIC CHAGAS DISEASE WITH POSACONAZOLE AND BENZNIDAZOLE
The investigators propose the evaluation of posaconazole and benznidazole in humans for the treatment of Chagas disease chronical infection. Exploratory trial of posaconazole antiparasitic activity against Trypanosoma cruzi.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
International Health Unit Metropolitana Nord
Santa Coloma, Barcelona, Spain
Infectious Disease Department Vall d'Hebron Hospital
Barcelona, Spain
International Health Unit Drassanes
Barcelona, Spain
Start Date
September 1, 2010
Primary Completion Date
December 1, 2012
Completion Date
March 1, 2013
Last Updated
September 10, 2013
78
ACTUAL participants
Benznidazole
DRUG
Posaconazole
DRUG
Lead Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Collaborators
NCT06632600
NCT03981523
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00123916